- Home
- BPTH vs MBRX Comparison
BPTH vs MBRX Comparison
Compare BPTH & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- MBRX
- Stock Information
- Founded
- BPTH 2007
- MBRX 2015
- Country
- BPTH United States
- MBRX United States
- Employees
- BPTH N/A
- MBRX N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- BPTH Health Care
- MBRX Health Care
- Exchange
- BPTH Nasdaq
- MBRX Nasdaq
- Market Cap
- BPTH 4.8M
- MBRX 5.1M
- IPO Year
- BPTH N/A
- MBRX 2016
- Fundamental
- Price
- BPTH $0.73
- MBRX $1.00
- Analyst Decision
- BPTH Strong Buy
- MBRX Strong Buy
- Analyst Count
- BPTH 2
- MBRX 2
- Target Price
- BPTH $30.00
- MBRX $24.00
- AVG Volume (30 Days)
- BPTH 161.7K
- MBRX 38.4K
- Earning Date
- BPTH 03-07-2025
- MBRX 03-21-2025
- Dividend Yield
- BPTH N/A
- MBRX N/A
- EPS Growth
- BPTH N/A
- MBRX N/A
- EPS
- BPTH N/A
- MBRX N/A
- Revenue
- BPTH N/A
- MBRX N/A
- Revenue This Year
- BPTH N/A
- MBRX N/A
- Revenue Next Year
- BPTH N/A
- MBRX N/A
- P/E Ratio
- BPTH N/A
- MBRX N/A
- Revenue Growth
- BPTH N/A
- MBRX N/A
- 52 Week Low
- BPTH $0.59
- MBRX $0.40
- 52 Week High
- BPTH $10.00
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- BPTH 37.30
- MBRX 31.81
- Support Level
- BPTH $0.78
- MBRX $1.33
- Resistance Level
- BPTH $0.84
- MBRX $1.82
- Average True Range (ATR)
- BPTH 0.05
- MBRX 0.13
- MACD
- BPTH -0.02
- MBRX -0.02
- Stochastic Oscillator
- BPTH 4.05
- MBRX 13.17
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.